Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...

Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...

Wall Street stocks were in the green at the close of trading on Friday as traders prepped for a three-day break.

On the macro front, building permits decreased by 0.7% month-on-month in December to a seasonally adjusted rate of 1.48m, ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...